IP Verse

Regeneron Pharmaceuticals, Inc. V. Samsung Bioepis Co., Ltd. - 1:23-cv-00106

Explore the details of the Regeneron Pharmaceuticals, Inc. V. Samsung Bioepis Co., Ltd. case under case number 1:23-cv-00106 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:23-cv-00106
Filing Date
Dec 27, 2023
Cause of Action
Patent Infringement
Status
-
Nature of Suit
Patent

Parties Involved in the Case

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Samsung Bioepis Co., Ltd. -
Regeneron Pharmaceuticals, Inc. -

Patents Involved in the Case

Patents not found - set an alert to get notified when patents are added.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Jun 12, 2024MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024)Attachment
Jun 12, 2024MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024)Attachment
Jun 12, 2024MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024)Attachment
Jun 12, 2024MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024)Attachment
Jun 12, 2024MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024)Attachment
Jun 12, 2024MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024)Attachment
Jun 12, 2024MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024)Attachment
Jun 26, 2024RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024)Attachment
Jun 26, 2024RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024)Attachment
Jun 26, 2024RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024)Attachment
Jun 26, 2024RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024)Attachment
Jun 26, 2024RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024)Attachment
Jun 26, 2024RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024)Attachment
Jul 3, 2024REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024)Attachment
Jul 3, 2024REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024)Attachment
Jul 3, 2024REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024)Attachment
Jul 3, 2024REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024)Attachment
Jul 3, 2024REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024)Attachment
Jul 3, 2024REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024)Attachment
Jul 3, 2024REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024)Attachment